Polymyxin B (Sulfate): High-Purity Polypeptide Antibiotic for Multidrug-Resistant Gram-Negative Bacteria

Executive Summary: Polymyxin B (sulfate) is a polypeptide antibiotic mixture derived from Bacillus polymyxa, composed mainly of polymyxins B1 and B2 (APExBIO, 2024). It exhibits strong bactericidal action against multidrug-resistant Gram-negative bacteria, including Pseudomonas aeruginosa, by disrupting bacterial membranes through cationic detergent activity (Polymyxin B Sulfate: Advanced Tools…). In vitro, it enhances dendritic cell maturation via upregulation of CD86 and HLA molecules and activates ERK1/2 and NF-κB signaling (Yan et al., 2025). In vivo, Polymyxin B increases survival and reduces bacterial load in sepsis models. Its clinical use is limited by nephrotoxicity and neurotoxicity risks (Polymyxin B (Sulfate): Unraveling Mechanisms…).

Biological Rationale

Polymyxin B (sulfate) targets Gram-negative bacterial infections that are resistant to conventional antibiotics. It is effective against key pathogens, such as Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae (APExBIO). Its action is critical in settings where carbapenems and cephalosporins fail due to resistance mechanisms. The clinical and research demand for reliable agents against multidrug-resistant Gram-negative bacteria underpins the continued relevance of polymyxin B (Polymyxin B (Sulfate): Beyond Antibiosis…). Additionally, its immunomodulatory effects, such as promoting dendritic cell maturation, provide new avenues for studying host-pathogen interactions.

Mechanism of Action of Polymyxin B (sulfate)

Polymyxin B acts as a cationic detergent. It binds to the lipid A region of lipopolysaccharide (LPS) in Gram-negative bacterial outer membranes via electrostatic interactions. This disrupts membrane integrity, increasing permeability and leading to cell lysis (APExBIO). The antibiotic also promotes the maturation of human dendritic cells by upregulating co-stimulatory molecules CD86 and HLA class I/II, activating the ERK1/2 and IκB-α/NF-κB intracellular pathways (Yan et al., 2025). These dual actions—direct bactericidal effects and immune modulation—make polymyxin B a valuable tool for both therapeutic and experimental use.

Evidence & Benchmarks

• Polymyxin B (sulfate) demonstrates rapid, dose-dependent bactericidal activity against Pseudomonas aeruginosa in vitro and in murine bacteremia models (Yan et al., 2025).
• Exposure to polymyxin B upregulates CD86 and HLA-I/II on human dendritic cells, promoting immune cell maturation (Yan et al., 2025).
• Polymyxin B activates ERK1/2 and IκB-α/NF-κB signaling pathways in immune cells, linking its antibiotic and immunomodulatory functions (Yan et al., 2025).
• High-purity formulations (≥95%) from APExBIO ensure reproducible in vitro results and stability at -20°C in PBS (pH 7.2) up to 2 mg/ml (APExBIO).
• Use in clinical and preclinical settings is limited by nephrotoxicity and neurotoxicity, requiring strict monitoring of dose and renal function (Polymyxin B (Sulfate): Unraveling Mechanisms…).

For a more detailed mechanistic and translational overview, see Polymyxin B Sulfate: Advanced Tools for Gram-Negative Infection Research, which provides protocol-driven insights not covered in this molecular dossier.

Applications, Limits & Misconceptions

Polymyxin B (sulfate) is indicated for research on multidrug-resistant Gram-negative infections, including meningitis, urinary tract infections, and sepsis. Its immunomodulatory features enable its use in dendritic cell maturation assays and microbiome interaction studies (Polymyxin B (sulfate): Expanding Horizons…). The compound is also used for depleting Gram-negative bacteria in animal models to study microbiome-immune system interactions (Yan et al., 2025).

Common Pitfalls or Misconceptions

• Not effective against Gram-positive bacteria or most fungi: Polymyxin B primarily targets Gram-negative bacteria, with variable or minimal activity against Gram-positive organisms and some fungi (APExBIO).
• Potential for nephrotoxicity and neurotoxicity: Clinically significant adverse effects require careful dosing and monitoring (Polymyxin B (Sulfate): Unraveling Mechanisms…).
• Stability limitations: Polymyxin B solutions are recommended for short-term use only and should be stored at -20°C to maintain activity (APExBIO).
• Does not address resistance via target modification: Some Gram-negative bacteria may exhibit resistance due to modifications in lipid A, reducing binding affinity of polymyxin B (Polymyxin B (Sulfate): Precision Tools…).
• Not interchangeable with colistin/methanesulfonate: While both are polymyxins, pharmacokinetics and spectrum may differ (Polymyxin B (Sulfate): Beyond Antibiosis…).

Workflow Integration & Parameters

Polymyxin B sulfate (SKU C3090) from APExBIO is supplied with ≥95% purity. It is soluble up to 2 mg/ml in PBS (pH 7.2) and should be stored at -20°C. Solutions are recommended for immediate or short-term use to maintain stability and efficacy (Polymyxin B (sulfate)). For dendritic cell assays, typical concentrations range from 0.1–10 μg/ml, depending on experimental design (Yan et al., 2025). For in vivo bacteremia models, dosing is typically weight-adjusted (e.g., 1–10 mg/kg), with monitoring for nephro- and neurotoxicity. Strict documentation of solvent, storage, and batch is required for reproducibility. For more on integrating this product into complex immunomodulation workflows, see Polymyxin B (Sulfate): Precision Tools for Immunomodulation, which details dendritic cell and sepsis model optimization.

Conclusion & Outlook

Polymyxin B (sulfate) remains a critical research tool for multidrug-resistant Gram-negative bacterial infections and immunomodulation studies. High-purity, well-documented formulations such as APExBIO's C3090 ensure experimental reproducibility. Ongoing research addresses the compound’s immunological effects and seeks to mitigate its toxicity profile. This article updates and extends mechanistic and workflow guidance beyond previous summaries, including those focused on translational and microbiome research (Polymyxin B (Sulfate): Beyond Antibiosis…).